GlaxoSmithKline Accelerates Drug Discovery with Docker

GlaxoSmithKline’s mission is “to help people do more, feel better, and live longer”. Mining research data and previous patient trial data helps the company improve its ability to bring drugs to market successfully.

GSK Leverages Docker Enterprise to Improve Research and Accelerate Drug Discovery

Challenge


Prototyping new data science tools took 3 to 6 months, slowing down drug discovery and clinical trials.

Solutions


Docker Enterprise is the cornerstone of a “Edge Node On Demand” platform that secures and isolates research environments which include Cloudera and MongoDB. Each researcher gets an isolated, secure sandbox.

Results


Faster prototyping of analytics applications and the underlying technology stack allows scientists both inside and outside GSK to work more efficiently.

GSK By the Numbers

£30
Billion in Revenue

£3.9
Billion Invested in R&D

100,000
Employees

“Docker Enterprise allows GSK to support a multitude of tools and technologies and interfaces so that scientists can run data analysis at scale.”

Ranjith Raghunath

Director of Big Data Solutions

You may also like these customer stories